Watson Pharmaceuticals announced results of its Phase 3 study of Gelnique (oxybutynin chloride) 10% gel for the treatment of women with overactive bladder (OAB) and urinary urge incontinence. The 12-week study showed that 27 percent of women treated with Gelnique achieved complete urinary continence versus 15.6 percent treated with placebo. Study data will be presented at the American Urological Association’s (AUA) Annual Conference.
Gelnique is a quick-drying, clear and colorless, fragrance-free hydroalcoholic gel containing oxybutynin chloride, an antispasmodic antimuscarinic agent.
For more information call (800) 272-5525 or visit www.gelnique.com.